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The proneural transcription factor Neurogenin3
(Ngn3) plays a critical role in pancreatic endocrine
cell differentiation, although regulation of Ngn3 pro-
tein is largely unexplored. Here we demonstrate
that Ngn3 protein undergoes cyclin-dependent ki-
nase (Cdk)-mediated phosphorylation on multiple
serine-proline sites. Replacing wild-type protein
with a phosphomutant form of Ngn3 increases a
cell generation, the earliest endocrine cell type to
be formed in the developing pancreas. Moreover,
un(der)phosphorylated Ngn3 maintains insulin ex-
pression in adult b cells in the presence of elevated
c-Myc and enhances endocrine specification during
ductal reprogramming. Mechanistically, preventing
multi-site phosphorylation enhances both Ngn3 sta-
bility and DNA binding, promoting the increased
expression of target genes that drive differentiation.
Therefore, multi-site phosphorylation of Ngn3 con-
trols its ability to promote pancreatic endocrine dif-
ferentiation and to maintain b cell function in the
presence of pro-proliferation cues and could be
manipulated to promote and maintain endocrine dif-
ferentiation in vitro and in vivo.
INTRODUCTION
While endocrine cells represent only 1%–5% of the entire
pancreas, they play a crucial role in physiological processes
including glucose homeostasis; loss or dysfunction of b cells
can lead to diabetes. In vitro differentiation and transplantation
of bona-fide functional b cells can regulate blood sugar in dia-274 Developmental Cell 41, 274–286, May 8, 2017 ª 2017 The Autho
This is an open access article under the CC BY license (http://creativebetic mouse models (Pagliuca et al., 2014; Rezania et al.,
2014), while b cell protection or replacement in diabetic patients
may improve long-term glycemic control. Moreover, a fasting
and refeeding regime may lead to b cell regeneration, with
improvement of blood sugar regulation (Cheng et al., 2017).
However, further improvements in b cell replacement or regener-
ation require a comprehensive understanding of the generation
and maintenance of pancreatic endocrine cells in development
and adulthood.
During pancreatic development, endocrine cells originate from
bipotent ductal-endocrine progenitors in the embryonic ductal
epithelium that become specified to the endocrine lineage
upon expression of the pro-endocrine basic-helix-loop-helix
(bHLH) transcription factor Neurogenin3 (Ngn3 or Neurog3).
Overexpression of Ngn3 from the early pancreatic Pdx1 pro-
moter induces early and ectopic differentiation of islet cells
(Schwitzgebel et al., 2000), while controlled Ngn3 overexpres-
sion at defined developmental stages results in sequential for-
mation of the different endocrine cell types (Johansson et al.,
2007; Schwitzgebel et al., 2000). Furthermore, Ngn3 is a central
component of transcription factor reprogramming cocktails that
can trans-differentiate adult exocrine acinar cells into functional
b cells (Zhou et al., 2008), while cytokine-induced in vivo reprog-
ramming of acinar cells into b cells also requires the transition
through a Ngn3-positive stage, indicative of reversion back to
a progenitor-like phase that re-instates developmental programs
of endocrine differentiation (Baeyens et al., 2014). Ngn3 is also
required for adult b cell function (Wang et al., 2009).
While in adult pancreatic homeostasis new b cells are gener-
ated by proliferation of pre-existing b cells (Dor et al., 2004),
b cell regeneration upon specific types of injury and genetic
manipulation may require the reactivation of a population of
facultative stem cells expressing elevated functional Ngn3 (Al-
Hasani et al., 2013; Van de Casteele et al., 2013; Xu et al.,
2008). Ductal cells retain the capacity to differentiate to
endocrine islet cells in vitro after ectopic expression of Ngn3rs. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
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Figure 1. Ngn3 Is Phosphorylated on Multi-
ple Sites
(A) Six serine-proline (SP) sites in mouse Ngn3,
showing conservation across species.
(B) Schematic representation of the SP sites
mutated in 6S-A Ngn3 and 2S-A Ngn3.
(C) Western blot showing that Ngn3 is phosphor-
ylated in mammalian HEK cells; treatment with
and without phosphatase l (l-PP) is indicated.
(D) Western blot showing that 6S-A and 2S-A
Ngn3 are phosphorylated in insulinoma-derived
MIN6 cells, with tubulin as a loading control.
(E) Ngn3 immunostaining in E14.5 mouse embry-
onic pancreas; nuclei are counterstained with
DAPI (blue). Scale bars, 50 mm (E) and 10 mm (E’).
(F) Ngn3 expression and phosphorylation in HEK
cells overexpressing Ngn3 (Ngn3 o/e) compared
with E14.5 murine embryonic pancreas; l-PP,
phosphatase l.
Solid and open arrowheads in (C, D, and F) indi-
cate un(der)phosphorylated and phosphorylated
Ngn3, respectively. See also Figure S1.(Heremans et al., 2002), in particular when co-expressed with
other transcription factors (Lee et al., 2013). Moreover, pancre-
atic ductal cells can be expanded in vitro as 3D organoids for
an extensive period of time, yet maintain the capacity to differen-
tiate toward the endocrine lineage; a process that requires the
passage through an Ngn3-positive phase (Huch et al., 2013).
Overall, Ngn3 clearly plays a crucial role in endocrine cell gener-
ation, regeneration, and reprogramming, yet its regulation at the
level of Ngn3 protein has barely been investigated (Roark et al.,
2012; Sancho et al., 2014).
Focusing here on its post-translational modification, we show
that Ngn3 is phosphorylated on multiple serine-proline (SP) sites
by cyclin-dependent kinases (Cdks). A phosphomutant form of
Ngn3 expressed in place of the wild-type (WT) protein results
in perturbed regulation of endocrine cells in vivo. Mechanisti-
cally, we see that this phosphomutant Ngn3 is more stable
than the WT protein and also shows increased binding at key
downstream target genes. Compared with theWT protein, phos-
phomutant Ngn3 enhances expression of endocrine target
genes in reprogramed ductal cells, while also maintaining insulin
expression and blood glucose homeostasis in the presence of aDevelopc-Myc driven pro-proliferative stimulus
in vivo. We conclude that multi-site phos-
phorylation of Ngn3 controls its ability to
promote and maintain endocrine differ-
entiation in the embryonic and adult
pancreas.
RESULTS
Ngn3 Is Phosphorylated onMultiple
Sites by Cdks
Ngn3 is closely related to other bHLH
transcription factors, whose activity is
regulated by phosphorylation on SP sites,
e.g., Ngn2, Ascl1, Atoh1, and Olig2 (Ali
et al., 2011, 2014; Forget et al., 2014).Ngn3 contains six SP sites that can potentially be targeted by
proline-directed kinases such as Cdks, MAPKs, and ERKs,
and five of these sites are conserved across species (Figure 1A).
To investigate phosphorylation on SP sites, we expressed WT
Ngn3 or 6S-A Ngn3 (where all six SP sites had been mutated
to alanine-proline) (Figure 1B) in HEK cells, then compared
migration on SDS-PAGE. Ngn3 phosphorylation is demon-
strated by slower migration of WT compared with 6S-A Ngn3,
which is enhanced by phosphatase l (l-PP) treatment (Fig-
ure 1C). WT Ngn3 also migrates more slowly than 6S-A Ngn3
in MIN6 cells, derived from the islet cancer insulinoma (Ishihara
et al., 1993), as well as in mPAC cells derived from pancreatic
ductal adenocarcinoma (Yoshida and Hanahan, 1994) (Fig-
ure 1D). As reported previously (De Vas et al., 2015; Gradwohl
et al., 2000; Smith et al., 2010; Zhou et al., 2007), Ngn3 is highly
expressed in the developing embryonic pancreas in scattered
endocrine precursor cells (Figures 1E, E’, and S1A). Co-staining
with an epithelial marker at embryonic day 16 (E16) shows that
Ngn3 is expressed in cells of the ductal epithelium prior to
delamination (Figures S1B and S1B’) (Rukstalis and Habener,
2007). Endogenous Ngn3 from E14 embryonic pancreas alsomental Cell 41, 274–286, May 8, 2017 275
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Figure 2. Ngn3 Is Phosphorylated by
Cyclin-Dependent Kinases
(A) SDS-PAGE separation of in vitro translated
(IVT) radiolabeled WT Ngn3 or 6S-A Ngn3 incu-
bated in interphase (I) or mitotic (M) Xenopus ex-
tracts, treated with phosphatase l (l-PP), as
indicated, or (B) incubated in I extract plus cyclin B
D90; samples removed at increasing times. Solid
and open arrowheads indicate un(der)phosphor-
ylated and phosphorylated Ngn3, respectively.
(C) In vitro kinase assay showing IVT WT and 6S-A
Ngn3 proteins after incubation with human re-
combinant CYCLIN/CDKs, as labeled.
(D) Schematic of the activity of cyclin/Cdks in the
different phases of cell cycle.
(E) Western blot of HA-tagged Ngn3 expressed in
ductal mPAC cells after treatment with Cdk in-
hibitors, treatment of Ngn3 with l-PP as a positive
control for protein dephosphorylation, tubulin as
loading control.
(F) Graphs showing the relative amount of the
slowest migrating band of phosphorylated Ngn3,
compared with the total amount of Ngn3 protein.
n = 3 independent experiments, a representative
blot is shown. Mean ± SEM. Student’s t test,
*p < 0.05, **p < 0.01.shows SDS-PAGE retardation compared with samples treated
with phosphatase (Figures 1F and S1C), demonstrating phos-
phorylation of endogenously expressed Ngn3 protein.
Phosphorylation of Ngn3 on two C-terminal serines, one of
which is an SP site, has previously been reported to regulate
Ngn3 protein stability (Sancho et al., 2014). To determine
whether the phosphorylation of Ngn3 we observe is solely due
to phosphorylation on these two sites (mutated in 2S-A Ngn3,
Figures 1B and 1D), we compared SDS-PAGE migration of WT
Ngn3, 6S-A Ngn3, and a 2S-A Ngn3. 2S-A Ngn3 migrates faster
than WT Ngn3 (Figure 1D, open arrowhead), but more slowly
than 6S-A Ngn3 (Figure 1D, black arrowhead), indicating phos-
phorylation on more than two serines.
Ngn2 and Ascl1, homologs of Ngn3, are phosphorylated by
Cdks in a cell-cycle-dependent manner on multiple sites in the
N and C termini (Ali et al., 2011, 2014; Forget et al., 2014) (Figure
2D). To investigate whether Ngn3 phosphorylation is affected by
changing levels of Cdks, we turned to Xenopus egg extracts that
recapitulate an interphase (I) or mitotic (M) environment (Fig-
ure 2A) and have long been used to investigate Cdk-dependent
phosphorylation (Philpott and Yew, 2008). Compared with phos-
phomutant 6S-A Ngn3, WT Ngn3 migration on SDS-PAGE is
slowed in I and evenmore so in M extract, a retardation reversed
by phosphatase treatment (Figure 2A). Addition of non-degrad-
able cyclin B to I extract directly activates Cdk1 and induces
its entry into M phase after 30–40 min. This is paralleled by pro-
gressive retardation of WT Ngn3 migration (Figure 2B).276 Developmental Cell 41, 274–286, May 8, 2017Xenopus I egg extracts have active
cyclin E/Cdk2, while addition of non-
degradable cyclin B will activate Cdk1
as extracts enter mitosis. However, cyclin
D/Cdk4 is not present in eggs (Philpott
and Yew, 2008). To determine whichCdks are capable of phosphorylating Ngn3, we undertook
in vitro kinase assays using human recombinant Cdk/cyclin
pairs. Slowed migration on SDS-PAGE reveals that Ngn3 can
be phosphorylated by all the Cdks tested, but to differing ex-
tents. Retardation of SDS-PAGE migration indicates that Cdk1
is the most potent kinase for Ngn3, supporting our findings in
Xenopus egg extracts (Figure 2C), while Cdk4 phosphorylation
results in the smallest migration change (Figure 2C). 6S-A
Ngn3 migration is unaffected by incubation with Cdk2 or Cdk4,
indicating that these kinases phosphorylate on SP sites (Fig-
ure 2C). A small retardation of 6S-A Ngn3 is observed with
Cdk1, as well as after incubation in M extract (Figures 2B and
2C); we note that 6S-A Ngn3 has one threonine-proline site
that remains a potential target site for Cdk1.
To further explore the identity of Cdks phosphorylating Ngn3 in
mammalian cells, we treated Ngn3-expressing cells with Rosco-
vitine, an inhibitor with selectivity for Cdk1/2 (and 5), alongside
Palbociclib, an inhibitor of Cdk4/6 (Asghar et al., 2015; Meijer
and Kim, 1997). Only the faster migrating form of Ngn3 remained
after Roscovitine treatment, while the Ngn3 doublet was
clearly still visible in Palbociclib (Figure 2E). We noted that
Roscovtitine and Palbociclib suppressed overall Ngn3 levels,
consistent with off-target effects suppressing the transcriptional
Cdks, Cdk7, and Cdk9 (Asghar et al., 2015). Therefore, to
mitigate against any effects of loss of overall Ngn3 protein, we
quantitatively compared the amount of the slower-migrating
form of Ngn3 with total Ngn3 protein in three independent
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Figure 3. 6S-A Ngn3 Enhances a and d Cells in the Embryonic Pancreas
(A) WT and 6S-A Ngn3 mouse model schematic.
(B and C) Immunohistochemistry for eYFP (green), glucagon (red), and insulin (gray) in E16 embryonic pancreas from WT (B) and 6S-A (C) Ngn3 animals, nuclei
counterstained with DAPI (blue). Scale bar, 200 mm.
(D and E) Quantification of the percentage of areas that are eYFP+, insulin+, glucagon+ (D), somatostatin+ (Sst), and pancreatic polypeptide Y+ (Ppy) (E), in E16
embryonic pancreas. n = 4 mean ± SEM. Student’s t test, *p < 0.05, **p < 0.01.
(F) Relative hormone gene expression in adult pancreatic islets by qPCR, normalized to EF-1a expression. n = 3 mean ± SEM. See also Figures S2–S4.experiments, with and without kinase inhibitors (Figures 2E and
2F). Roscovitine treatment resulted in a relative accumulation
of faster-migrating un(der)phosphorylated Ngn3 forms, while
Palbociclib has no detectable effect on Ngn3 phosphorylation
(Figures 2E and 2F).
Thus, we see that Ngn3 is directly phosphorylated by Cdks,
and in particular Cdk1 and Cdk2. Ngn3 can be phosphorylated
by high levels of Cdk4 in vitro, but failure to observe Ngn3
dephosphorylation in response to Palbociclib indicates that
Cdk4 is not a major kinase for Ngn3 in mPAC cells. Instead,
our evidence is consistent with a more prominent role for Cdk1
and Cdk2 compared with Cdk4 in the phosphoregulation of
Ngn3 in pancreatic cells. We next investigated the functional
consequences of preventing Cdk-dependent Ngn3 phosphory-
lation during pancreas formation.Ngn3 Phosphorylation Controls the Number of
Endocrine Cells in the Embryonic Pancreas
Ngn3 plays a major role in endocrine specification and differen-
tiation during development (Gradwohl et al., 2000; Rukstalis and
Habener, 2009). To determine whether phosphorylation status of
Ngn3, expressed at the normal time and at endogenous levels,
can influence endocrine cell fate, we generated a knockin mouse
that carries 6S-A Ngn3 separated from eYFP by 2A peptide, and
transcribed homozygously from the Ngn3 locus, with a matched
control WT Ngn3 eYFP mouse line (Figures 3A and S2A). As ex-
pected, in the embryonic pancreas, 6SA Ngn3 is dephosphory-
lated, running as a single, faster-migrating form compared with
the WT protein (Figure S2B). To determine the developmental
effects of preventing phosphorylation of Ngn3, we then quanti-
fied the relative amount of the distinct endocrine cell types inDevelopmental Cell 41, 274–286, May 8, 2017 277
WT Ngn3 and 6S-A Ngn3 mice (percentage of hormone-positive
area normalized to total DAPI area) at embryonic stage E16
(Johansson et al., 2007; Rukstalis and Habener, 2009), when
endocrine cells will be largely specified (Figures 3B–3E, S3A,
and S3B). Glucagon-positive cells are the first cell type to
arise during pancreatic endocrine differentiation and numbers
approximately double in 6S-ANgn3 animals comparedwith con-
trols (3.3%± 0.5%versus 1.8%± 0.2%, n = 4) (Figure 3D). Insulin
or Ppy-positive cells are very similar in WT and 6S-A Ngn3 ani-
mals. Somatostatin (Sst)-positive cells also significantly increase
(0.1% ± 0.01% in 6S-A Ngn3 compared with 0.04% ± 0.006% in
Ngn3 WT, n = 3) (Figure 3E). We also observed a trend toward
more eYFP+ cells (marking Ngn3 expression) in 6S-A embryonic
pancreata (Figures 3B–3D), which did not reach statistical signif-
icance and this result was consistent with our quantification of
Ngn3 protein staining (Figures S3C–S3E).
We then investigated the composition of the adult endocrine
compartment in 6S-A Ngn3 mice, when Ngn3 levels have
substantially dropped (Rukstalis and Habener, 2009). Firstly,
we quantified the total number of islets and the islet size
distribution in WT and 6S-A mouse adult pancreata and we
found no major differences (Figures S4A and S4B). We then
measured the insulin- and glucagon-positive regions of the
pancreas (as a percentage of total pancreas) and also found
no significant differences (Figure S4C). We note that qPCR to
detect hormone transcripts in isolated adult islets demon-
strates a trend toward higher glucagon and Sst in the 6S-A
Ngn3-expressing pancreata, yet neither reach statistical signif-
icance (p > 0.05) (Figure 3F). Thus, perturbation of the
balance of endocrine subtypes brought about by preventing
phosphorylation of Ngn3 can be at least partially compen-
sated in the normal adult pancreas, which may reflect the
previously described post-natal compensatory mechanisms
that rebalance a and b cells (Collombat et al., 2009; Thorel
et al., 2010).
Ngn3 Phosphorylation Regulates Transcription of
Endocrine Genes in Pancreatic Organoids
Cell proliferation, and the Cdk activity that drives it, is generally
associated with maintenance of progenitors, while cell-cycle
lengthening and exit with a corresponding reduction of Cdk
activity, accompanies differentiation (Hardwick et al., 2015;
Hardwick and Philpott, 2014). We see that 6S-A Ngn3 causes
an increase in glucagon-expressing a cells when expressed
from the endogenous locus (Figures 3B–3D). As a cells are the
first endocrine cell type to be generated during pancreatic devel-
opment, the increase in a cells would be consistent with an
accelerated differentiation activity of 6S-A Ngn3. We therefore
wanted to investigate whether preventing Cdk-dependent phos-
phorylation of Ngn3 might enhance expression of downstream
targets of Ngn3 that potentiate the differentiation program. To
this end, we tested the relative ability of WT and 6S-A Ngn3 to
activate endocrine differentiation targets in 3D pancreatic ductal
organoids, which exhibit characteristics typical of in vivo pancre-
atic progenitors such as extensive growth and endocrine differ-
entiation potential (Huch et al., 2013). Induction of lentivirally
transduced Ngn3 results in similar expression of WT Ngn3 and
6S-A Ngn3 mRNAs (Figures 4A and 4B). However, expression
of NeuroD1 and Insm1, downstream targets of Ngn3 that are278 Developmental Cell 41, 274–286, May 8, 2017key regulators of endocrine differentiation (Huang et al., 2000;
Mellitzer et al., 2006), is 2- to 3-fold higher in 6S-A Ngn3-trans-
duced organoids (Figure 4B).
To further characterize the Ngn3-driven transcriptional pro-
gram that can be upregulated in ductal organoids, we sorted
pools of 50 Ngn3-expressing cells and undertook genome-
wide transcriptional profiling, determining gene expression at 2
and 8 days after upregulation of WT or 6S-A Ngn3. Ngn3 is a
transcriptional activator, so we focused our analysis on the top
200 upregulated genes as potential Ngn3 targets. We found
many genes that were previously described to play important
roles in endocrine differentiation such as Neurod1, Insm1,
Atoh8, and Rfx6 (Figures 4C and S5; Table S1) (Smith et al.,
2010). Activation of a pro-endocrine differentiation program is
also confirmed by gene ontology analysis (Table S1), while other
terms indicate upregulation of genes involved in neuronal differ-
entiation, reflecting the close parallels between Neurogenin-
driven differentiation in the two tissues (Otter and Lammert,
2016; van Arensbergen et al., 2010). Importantly, we see that
6S-A Ngn3 drives expression of the same genes as WT Ngn3,
but it does so to a consistently higher level (p % 0.005)
(Figure 4D), an effect that is magnified between 2 and 8 days
post-expression (Figures 4C, 4D, and S5). Thus, preventing
Cdk-mediated phosphorylation of Ngn3 results in an enhance-
ment of its ability to upregulate transcriptional targets that drive
the endocrine differentiation program. We next investigated the
mechanistic basis for the enhanced activity of un(der)phosphor-
ylated Ngn3.
Phosphorylation of Ngn3 Regulates Protein Stability and
Binding to Targets
Enhanced activity of 6S-A Ngn3 protein could reflect increased
stability (Sancho et al., 2014) or enhanced association with
the regulatory regions of downstream target genes, or both.
Phosphorylation-dependent recruitment of E3 ubiquitin ligases
to bHLH transcription factors has been shown to control
protein degradation (Forget et al., 2014; Sancho et al., 2014).
In insulinoma-derived MIN6 cells, we see that 6S-A Ngn3 is
five times as stable as WT Ngn3 (half-life 52.3 ± 7.9 min
compared with 11.7 ± 2.8 min) (Figures 5A, 5B, and 5D). Phos-
phorylation of two serines of Ngn3 (mutated here in 2S-A
Ngn3) promotes Ngn3 degradation via recruitment of the E3
ubiquitin ligase Fbxw7 (Sancho et al., 2014), and one of these
sites is also mutated in 6S-A Ngn3 (Figure 1B). Comparing
the stability of these proteins, 2S-A Ngn3 is twice as stable
as WT Ngn3 (half-life of 23.1 ± 2.8 min compared with 11.7 ±
2.8 min), but considerably less stable than 6S-A Ngn3 (half-
life 52.3 ± 7.9 min) (Figures 5C and 5D), showing that sites
additional to those mutated in 2S-A Ngn3 contribute to
the phosphorylation-dependent regulation of Ngn3 protein
stability.
To investigate whether enhanced transcription of targets by
6S-A Ngn3 is solely due to increased half-life, we expressed
WT or 6S-A Ngn3 in mPAC cells and determined Ngn3 binding
at key target genes by chromatin immunoprecipitation (ChIP),
after normalizing for the amount of chromatin-bound Ngn3 pro-
tein (Figure S6A). Even when normalized for protein level, 6S-A
Ngn3 binding is more than 2-fold greater than WT Ngn3 on pro-
moters of Insm1 and NeuroD1, and 5-fold greater at predicted
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Figure 4. 6S-A Ngn3 Shows Enhanced Target
Gene Expression in Pancreatic Organoids
(A) Inducible lentiviral vectors (illustrated) were used
to infect ductal organoid cultures, images 2 days
post-induction. Scale bars, 100 mm.
(B) Relative mRNA expression of Ngn3 and its
downstream targets Neurod1 and Insm1 after
2 days of Ngn3 expression in organoids, normalized
to b-actin. Data are mean ± SEM (n = 3). Student’s
t test, *p < 0.05, **p < 0.01.
(C) Genome-wide transcriptomic analysis of
pancreatic organoids expressing WT and 6S-A
Ngn3. Graph showing the relative fold-change of
expression in 6S-A Ngn3 organoids compared with
WT Ngn3 fold-change (WT Ngn3 set as 1 unit) at
8 days after Ngn3 induction. Data represent mean
fold change ± SEM (n = 3).
(D) Average relative log2 fold-change of expression
in potential Ngn3 targets compared with control (all
genes excluding Ngn3 targets) at 8 days. Data
represent average log2 fold change and error bars
represent 95% confidence intervals of the mean
(n = 3). **p < 0.01. See also Figure S5.target E boxes of the Delta1 promoter (Figure 5E). Hence,
enhanced protein stability and increased binding to downstream
regulatory elements both contribute to the increased transcrip-
tional activity of 6S-A Ngn3.
The enhanced NeuroD1 and Insm1 expression in response to
6S-A Ngn3 might explain the increased generation of a cells
observed during embryonic development, which would be
consistent with an early entry into the differentiation program
(Figures 3B–3E). However, in addition to more early-born a
cells, 6S-A Ngn3 mice also show enhanced Sst expression
despite the fact that d cells arise later in development (Figures
3B–3E). Ngn3 expression alone is sufficient to reprogram acinar
cells into d cells (Li et al., 2014). We determined by ChIP that
Ngn3 binds directly to two consecutive E boxes found in the
30 genomic region of Sst (Figure S6B), and this binding is
increased 6.9- ± 2.3-fold by 6S-A Ngn3 compared with WT
Ngn3 (Figure S6C). Moreover, we also see that Sst mRNA is
upregulated by Ngn3 in this cell line (Figure S6D), indicating
that Sst is a bone fide direct target of Ngn3. Therefore, the
increased expression of Sst in the 6S-A Ngn3 E16 pancreas
is likely to reflect enhanced Sst promoter binding and activation
of 6S-A Ngn3 compared with WT Ngn3.DeveloUn(der)phosphorylated Ngn3
Maintains Adult b Cell Mature
Identity in the Presence of Elevated
c-Myc
Ngn3 is expressed at high levels during
development and its expression is main-
tained at low levels in adult b cells (Fig-
ure 6A), where it is still required to maintain
efficient function (Wang et al., 2009).
Following on from our results demon-
strating the enhanced capacity of 6S-A
Ngn3 to promote differentiation in devel-
opment and in organoid culture, we nextinvestigated whether Ngn3 phosphorylation influences adult
endocrine cell differentiation in islets that have been stimulated
to proliferate. C-Myc upregulation in adult islets in a mouse
model of insulinoma has a potent pro-proliferative effect and
also results in loss of insulin expression and a failure to maintain
blood glucose homeostasis (Pelengaris et al., 2002).
In the Ins-cMycERTAM model that we have used (Pelengaris
et al., 2002), rapid c-Myc activation occurs in islets in response
to tamoxifen and under the control of the insulin promoter; exten-
sive b cell apoptosis results, but this can be counteracted by co-
expression of the apoptotic inhibitor Bcl-xL. To determine
whether the phospho-status of Ngn3 could influence adult islet
cell function, we compared Ins-cMycERTAM Bcl-xL mice that
were also homozygous for WT or 6S-A Ngn3, using Bcl-xL only
mice as a control (Figure 6B).
In this model, over a 7 day period Ins-cMycERTAM Bcl-xL islet
expansion is accompanied by reduced insulin expression in
b cells with accompanying hyperglycemia (Pelengaris et al.,
2002) (Figure 6D). We compared glucose homeostasis 0, 4,
and 7 days after tamoxifen-induction of c-Myc in WT Ngn3-
and 6S-A Ngn3-expressing mice. In control conditions (BclX-
xL WT or 6S-A Ngn3), glycemic values vary within the normalpmental Cell 41, 274–286, May 8, 2017 279
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B C Figure 5. Ngn3 Phosphorylation Controls
Protein Stability and Binding to Target
Genes
(A–C) HA-tagged WT Ngn3 (A), 6S-A (B), and 2S-A
Ngn3 (C) protein expression following cyclohexi-
mide (CHX) addition (in min). (D) Graph showing
degradation rate for different Ngn3 mutants,
normalized to tubulin. n = 3 independent experi-
ments, mean ± SEM. Student’s t test, *p < 0.05,
**p < 0.01, ****p < 0.0001.
(E) Chromatin immunoprecipitation (ChIP) from
ductal mPAC cell extracts containing normalized
amounts of HA-tagged Ngn3 WT and 6S-A. Data
represent mean ± SEM. (n R 3) Student’s t test,
*p < 0.05, ***p < 0.001. See also Figure S6.range, between 9.5 and 13.1mmol/L (Figure 6C), while c-Myc in-
duction in Ins-cMycERTAM Bcl-xLWTNgn3 raises blood glucose
levels after 4 and 7 days of tamoxifen treatment to 24.25 ± 5.2
and 30.7 ± 4.9 mmol/L, respectively. Strikingly however, Ins-
cMycERTAM Bcl-xL 6S-A Ngn3 mice maintain glucose levels
within the normal range (10.6 ± 1.3 mmol/L at 4 days and 16 ±
3.3 mmol/L at 7 days post-induction) (Figure 6D). Perhaps sur-
prisingly, we see that massive islet expansion occurs to an equal
extent in Bcl-xLWT Ngn3 and Bcl-xL 6S-A Ngn3 animals treated
with tamoxifen for 7 days (Figures S7A–S7C). Thus, islet expan-
sion occurs in response to c-Myc in Ins-cMycERTAM Bcl-xL 6S-A
Ngn3 mice, demonstrating that b cells expressing 6S-A Ngn3
can still proliferate. However, even though c-Myc can drive b
cell expansion in both WT and 6S-A Ngn3 mice, blood glucose
control is only maintained in 6S-A Ngn3 mice. Therefore, block-
ing its phosphorylation allows Ngn3 to maintain differentiated
function of b cells even while they are actively proliferating.
To investigate directly whether the expanded islets in 6S-A
Ngn3 mice could maintain insulin expression even in the face
of c-Myc overexpression, we used immunohistochemistry to
detect insulin protein. After quantitation of hormone intensity
in stained islets (see STAR Methods for details of analysis),
we find that insulin and glucagon levels are very similar in the
control Bcl-xL WT Ngn3 and Bcl-xL 6S-A Ngn3 animals after
7 days of tamoxifen (Figures 6E–6G). However, Ins-cMycERTAM
Bcl-xL 6S-A Ngn3 animals maintain insulin expression at twice
the level of Ins-cMycERT Bcl-xL WT Ngn3 mice (a relative in-
tensity of 40.5 ± 8.4 in Ins-cMycERT; Bcl-xL; 6S-A Ngn3
compared with 20 ± 1.7 in Ins-cMycERT; Bcl-xL; WT Ngn3)
(Figures 6F–6H). No differences in glucagon expression are
observed, consistent with the fact that Ngn3 is not known to
be expressed in a cells. Thus, results from 6S-A Ngn3 mice
suggest enhanced expression of insulin in proliferating islets
compared with WT mice, while showing no differences in
expression of glucagon, indicating a cell-autonomous effect.
However, further experiments looking directly at insulin secre-
tion would be needed to confirm that enhanced insulin produc-
tion arising from dephosphorylation of Ngn3 is responsible for280 Developmental Cell 41, 274–286, May 8, 2017maintenance of glucose homeostasis in
Ins-cMycERT; Bcl-xL; 6S-A Ngn3 mice.
To investigate more directly whether
preventing Ngn3 phosphorylation limits
c-Myc-mediated inhibition of Ngn3 activ-ity in another context, we tested the ability of WT and 6S-A Ngn3
to activate Insm1 and Neurod1 in Xenopus embryos, with and
without co-injected c-Myc. As we saw in mammalian cells,
ectopic 6S-A Ngn3 resulted in greater expression of Insm1 and
Neurod1 than WT Ngn3. C-Myc overexpression suppresses
Ngn3-driven Neurod1 and Insm1 expression, but levels never-
theless remain higher with 6S-A Ngn3 compared with WT
Ngn3 (Figure S7D). As Ngn3 and c-Myc are co-injected, this is
likely to represent a cell-autonomous effect.
Regulation of Cell-Cycle Exit by Ngn3 Phosphorylation
A recent study demonstrates that a low level of Ngn3 in pancre-
atic endocrine cell progenitors is compatible with continued pro-
liferation and maintenance of a precursor state (Bechard et al.,
2016). However, increasing Ngn3 expression drives endocrine
commitment, cell-cycle exit, and finally endocrine cell differenti-
ation (Bechard et al., 2016; Miyatsuka et al., 2011). As well as
potentiating endocrine differentiation, we see that 6S-A Ngn3
drives cell-cycle exit more effectively than WT Ngn3 in mPAC
cells (Figure 7A and 7B). Since Ngn3 is known to drive the cell cy-
cle in endocrine progenitors by upregulating Cdkn1a expression
(Miyatsuka et al., 2011), an inhibitor primarily of Cdk2, we inves-
tigated Cdkn1a regulation by WT and 6S-A Ngn3. 6S-A Ngn3
binds to the Cdkn1a distal regulatory region (Miyatsuka et al.,
2011) (Figure 7C), and activates Cdkn1a expression to a greater
extent than WT Ngn3 (Figure 7D), consistent with its enhanced
ability to drive cell-cycle exit (Figures 7A–7D). Hence, Ngn3
both drives Cdk inhibition and cell-cycle exit as well as respond-
ing to it, because of an enhanced ability of un(der)phosphory-
lated Ngn3 to upregulate the endocrine differentiation program
(Figure 7E).
DISCUSSION
The role of Ngn3 in pancreatic endocrine cell fate specification
and differentiation has been extensively studied, but surprisingly
little is known about the activity and regulation of Ngn3 protein
(Roark et al., 2012; Rukstalis and Habener, 2009; Sancho
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Figure 6. 6S-A Ngn3 Maintains Insulin Expression in Adult b Cells Expressing c-Myc
(A) eYFP expression in live culture of Ngn3-eYFP islets. Scale bar, 40 mm.
(B) Schematic representation of animal models used for in vivo insulinoma analysis.
(C and D) Quantification of blood glucosemeasurements (in mmol/L) in Bcl-xL (C) and Ins-cMycERTAM Bcl-xL (D) mice at 0, 4, and 7 days of tamoxifen treatment.
nR 4 mean ± SEM. Student’s t test, *p < 0.05.
(legend continued on next page)
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et al., 2014). Here we show that Ngn3 is phosphorylated on up to
six sites by Cdks. Inhibition of Cdk-dependent phosphorylation
enhances pancreatic endocrine differentiation both by stabilizing
Ngn3 protein and additionally by enhancing its ability to bind to
downstream targets. Importantly, we show that preventing
phosphorylation of Ngn3 expressed at the endogenous level is
sufficient to promote enhanced differentiation of glucagon- and
somatostatin-expressing cells in the developing pancreas.
Furthermore, even in the face of forced c-Myc expression and
a significant drive toward decreased insulin production, 6S-A
Ngn3 expressed from the endogenous promoter is sufficient to
maintain b cell function.
Our data allow us to propose a model of Ngn3 post-transla-
tional regulation that can explain how endocrine precursors tran-
sition from proliferating progenitors to endocrine cells firmly
committed to undergoing differentiation (Figure 7E). In prolifer-
ating progenitors, Ngn3 expression levels are low and Cdk levels
are high, resulting in extensive Ngn3 phosphorylation. Low levels
of phosphorylated Ngn3 are compatible with, and may be
required for, endocrine progenitor maintenance (Bechard et al.,
2016). Firm endocrine commitment coincides with a rise in
Ngn3 transcripts (Bechard et al., 2016), and this rising Ngn3 re-
sults in increased expression of its direct target Cdkn1a (Figures
7C and 7D), which predominantly inhibits Cdk2. Cdk inhibition
then results in both slowing of the cell cycle and in limiting the
Cdk-dependent phosphorylation of Ngn3. Moreover, Ngn3 is
directly stabilized by the Cdkn1a homolog p27Xic1 in Xenopus
(Roark et al., 2012). Therefore, as cells pass through endocrine
commitment with increasing Cdkn1a levels and falling Cdk activ-
ity, Ngn3 protein levels will rise through a combination of
elevated expression (Bechard et al., 2016) and enhanced protein
stability, while its association with regulatory regions of down-
stream targets driving differentiation will also increase. This
rise in un(der)phosphorylated Ngn3 activity drives further in-
creases in activation of downstream targets of Ngn3 such as
Cdkn1a, Insm1, and Neurod1, ultimately leading to cell-cycle
exit, endocrine commitment, and then differentiation in a feed-
forward loop.
Ngn3 expression is highest at endocrine commitment in devel-
opment, with levels dropping dramatically after this point coin-
ciding with terminal differentiation (Villasenor et al., 2008; Zhou
et al., 2008). Our model of Ngn3 phosphoregulation coupling
cell cycle and differentiation can help to explain the transition
from proliferating progenitor to differentiating endocrine cell dur-
ing development when Ngn3 is highly expressed. However,
whether the same couplingmechanisms aremaintained in adults
in homeostasis or during tissue repair has been unclear.
Ngn3 is required for adult b cell function (Wang et al., 2009)
and we see that phosphorylation of Ngn3 may play a regulatory
role in maintaining b cell function in the presence of pathological
pro-proliferative cues. In a model for the human islet cancer
insulinoma, b cells can be driven to proliferate by c-Myc overex-
pression and this is usually accompanied by loss of insulin(E and F) Immunohistochemistry to detect insulin (red) and glucagon (green) in adu
crossed with WT or 6S-A Ngn3 mice, as labeled, at 7 days of tamoxifen. Nuclei
(G and H) Quantification of hormone intensity, divided by islet area in Bcl-xL (G) an
at 7 days of tamoxifen. Data represent mean ± SEM. nR 3 different animals (islet
Methods for details). Student’s t test, *p < 0.05. See also Figure S7.
282 Developmental Cell 41, 274–286, May 8, 2017expression (Pelengaris et al., 2002). However, 6S-A Ngn3-ex-
pressing islets maintain insulin expression and support glucose
homeostasis while still undergoing massive islet expansion (Fig-
ures 6 and S7). Interestingly, this demonstrates that expression
of un(der)phosphorylated Ngn3 alone is not sufficient to coun-
teract c-Myc-driven cell division and that even a high rate of b
cell proliferation is not fundamentally incompatible with differen-
tiated function (Dor et al., 2004).
Conditional ablation of Ngn3 in adult b cells results in mild
glucose intolerance and decreased expression of classical
b cell markers, thus pointing toward an essential role for Ngn3
in maintaining mature b cell identity (Wang et al., 2009). There
is also increasing evidence that b cell de-differentiation and a
concomitant increase in Ngn3 expression may significantly
contribute to the pathogenesis of diabetes (Talchai et al.,
2012). Moreover, a very recent study has showed that subjecting
diabetic mice to a fasting/refeeding regime results in regenera-
tion of new b cells, a phenomenon that can reverse the diabetic
phenotype (Cheng et al., 2017). In this model, more b cells arise
after refeeding via a proliferating population of cells newly ex-
pressing elevated Ngn3, which in many ways resemble Ngn3-
expressing developmental endocrine precursors (Bechard
et al., 2016). These cells subsequently differentiate into insulin-
secreting mature b cells. We would predict that Ngn3 dephos-
phorylation plays a role in transitioning from a precursor-like
state to a functional b cell on refeeding. This study also shows
that applying a ‘‘fasting-mimicking’’ growth factor medium to hu-
man type 1 diabetic islets induces expression of Ngn3 and insu-
lin, but when insulin growth factor 1 (IGF-1) was added, Ngn3
expression remained but insulin was lost, essentially indicating
a block of islet differentiation. It would be very interesting to
determine whether Ngn3 is phosphorylated in these IGF-1-
treated type 1 diabetic islets; IGF-1 has been shown to enhance
mouse b cell proliferation (Agudo et al., 2008), which potentiates
Ngn3 phosphorylation by Cdks, thus inhibiting its ability to drive
and maintain b cell differentiation. Moreover, as many b cell-
generating protocols transit a Ngn3-positive phase (Melton,
2016), it will be interesting to see whether dephosphorylation
of endogenously expressed Ngn3 protein will similarly enhance
differentiation and maturation of b cells generated in vitro.
bHLH transcription factors play a central role in progenitor
maintenance and differentiation in the nervous system,
pancreas, gut, and many other tissues. In most cases, the levels
of bHLH gene expression have been well documented (Bertrand
et al., 2002), but protein level and activity is much less clear. The
multi-site phosphoregulation of Ngn3 we describe here is highly
reminiscent of that seen in other proneural proteins that are
master regulators of neurogenesis in the central and peripheral
nervous systems. For instance, ectopic overexpression of a
nine SP site phosphomutant form of Ngn2 in Xenopus results
in substantially enhanced reprogramming of the epidermis into
neurons compared with the WT protein (Ali et al., 2011), while
Ngn2 protein is stabilized by the Cdkn1a homolog p27Xic1lt pancreatic sections fromBcl-xL only (E) or Ins-cMycERTAM Bcl-xL (F) animals
were counterstained with DAPI. Scale bar, 50 mm in (E, F, F0, and F’’).
d Ins-cMycERTAM Bcl-xL crossed with WT or 6S-A Ngn3 mice, as indicated (H)
analyses, 2–6 different sections for each animal for each condition, see STAR
AE
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Figure 7. Ngn3 Dephosphorylation Enhances Cell-Cycle Exit in Pancreatic Ductal Cells
(A) Graph showing the growth of pancreatic ductal mPAC cells at 24, 48, and 72 hr after transfectionwithWT and 6S-A Ngn3 andGFP or GFP only, counting GFP+
cells. Data are mean ± SEM of four independent experiments. Student’s t test, *p < 0.05, **p < 0.01.
(B) Representative images of mPAC cells 72 hr after transfection. Scale bar, 100 mm.
(C) Chromatin immunoprecipitation (ChIP) from ductal mPAC cell extracts expressing HA-tagged WT and 6S-A Ngn3. Data represent mean ± SEM (n R 3).
Student’s t test, *p < 0.05.
(D) Relative mRNA expression ofCdkn1a after 2 days of Ngn3 expression in ductal PAC cells, normalized to b-actin. Data are mean ± SEM (n = 3). Student’s t test,
*p < 0.05, **p < 0.01.
(E) Model illustrating how Ngn3 phosphorylation controls the balance between proliferation and differentiation during development of the endocrine pancreas.
Cdk, cyclin-dependent kinase; Cdki, Cdk inhibitor; P, phosphorylation.(Nguyen et al., 2006; Vernon et al., 2003). Similar multi-site phos-
phorylation is also seen to inhibit the activity of ectopically ex-
pressed Ascl1 and NeuroD4 proteins (Ali et al., 2014; Hardwick
and Philpott, 2015; Wylie et al., 2015). It seems likely that post-translational regulation by Cdks is a common mechanism at
work widely among members of the bHLH family (Philpott,
2015). In these cases, and in the case of Ngn3 (Figures 4 and
5), an enhanced ability of un(der)phosphorylated proneuralDevelopmental Cell 41, 274–286, May 8, 2017 283
proteins to bind to the regulatory elements of their downstream
targets may underlie much of their increased transcriptional
activity, over and above any additional protein-stabilizing effect
of dephosphorylation in vivo (Ali et al., 2011, 2014; Hardwick
and Philpott, 2015; Hindley et al., 2012; our unpublished data).
Overall, Ngn3 regulation may serve as a paradigm for ensuring
the coordination of fate commitment, cell-cycle exit, and differ-
entiation by bHLH transcription factors in response to the cellular
environment in multiple tissues.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Guinea pig anti-insulin Abcam ab7842; RRID: AB_306130
Mouse anti-glucagon Abcam ab10988; RRID: AB_297642
Rabbit anti-somatostatin Dako A0566; RRID: AB_10013726
Goat anti-PPY Abcam ab77192; RRID: AB_1524152
Goat anti-Ngn3 Santa Cruz Biotechnology sc-13793; RRID: AB_650136
Mouse anti-Ngn3 DSHB F25A1B3; RRID: AB_528401
Rabbit anti-Ngn3 Gift of Dr. Edlund (Selander and
Edlund, 2002)
N/A
Rat anti-HA HRP conjugated Roche 12013819001; RRID: AB_390917
Rabbit anti-HA Abcam ab9110 RRID: AB_307019
Chicken anti-GFP Abcam ab13970 RRID: AB_300798
Mouse anti-Epcam APC eBioscience 17-5791-80; RRID: AB_1659714
Chemicals, Peptides, and Recombinant Proteins
Tamoxifen Sigma-Aldrich T5648
Lambda Protein Phosphatase New England Biolabs P0753S
Palbociclib isethionate selleckchem PD0332991
Roscovitine selleckchem S1153
CDK2/ CYCLIN A Thermo Fisher Scientific PV3267
CDK1/ CYCLIN B Thermo Fisher Scientific PV3292
CDK4/ CYCLIN D1 Thermo Fisher Scientific PV4400
CDK2/ CYCLIN E1 Abcam ab85639
EGF (organoid growth) Invitrogen PMG8043
FGF10 (organoid growth) Peprotech 100-26
Gastrin (organoid growth) Sigma G9145
Noggin (organoid growth) R&D System 1967
R-Spondin (organoid growth) In house (Huch et al., 2013) N/A
Critical Commercial Assays
Rnaesy Mini Kit Qiagen 74104
High-Capacity cDNA RT Kit Thermo Fisher Scientific 4368814
QuantiTect Reverse Transcription kit Qiagen 205310
LenitiX concentrator Clontech 631231
LentiX Titration Kit Clontech 631235
Advanced DMEM (organoid growth) Gibco 12634
Low Glucose DMEM (islet isolation) Media Tech 10-014-CM
Nextera Kit Illumina FC-131-1096
Illumina index Illumina FC-131-1002
Superscript II Life Technolgies 18064-014
Deposited Data
Organoid RNAseq data GEO GSE96707
Experimental Models: Cell Lines
mPAC L20 Douglas Winton laboratory
(Yoshida and Hanahan, 1994)
N/A
MIN6 Douglas Melton laboratory
(Ishihara et al., 1993)
N/A
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Experimental Models: Organisms/Strains
Mouse InsMycERTAM: Tg(Ins-MYC/Er)1Gev Gerard Evan laboratory RRID: MGI: 3821935
Mouse: Tg(Ins1-BCL2L1)1Ksp Gerard Evan laboratory MGI: 2384544
Mouse: WT-Ngn3eYFP Generated in our laboratory N/A
Mouse: 6S-A Ngn3eYFP Generated in our laboratory N/A
Recombinant DNA
pLVX-CMV-Tet3G Clontech 631358
pLVX-TREG Clontech 631193
pLVX-PGK-Tet3G This paper N/A
pCS2-Ngn3-HA This paper N/A
pCS2-6S-A Ngn3-HA This paper N/A
pCS2-2S-A Ngn3-HA This paper N/A
pLVX-TREG-GFP-P2A-WT Ngn3-HA This paper N/A
pLVX-TREG-GFP-P2A-6S-A Ngn3-HA This paper N/A
Sequence-Based Reagents
Primers for gene expression, see Table S2 This paper N/A
Taqman probes for gene expression, see Table S2 This paper N/A
Primers for Chip, see Table S2 This paper N/A
Primers for Xenopus experiment, see Table S2 This paper N/A
Software and Algorithms
ZEN Imaging software Carl Zeiss https://www.zeiss.com
Scran Bioconductor http://bioconductor.org/packages/release/
bioc/html/scran.html
DESeq2 Bioconductor https://bioconductor.org/packages/
release/bioc/html/DESeq2.htmlCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by, the Lead Contact, Anna Philpott (ap113@
cam.ac.uk)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Mice were housed, bred and treated according to the Home Office guidelines, under the Animal Scientific Procedure Act (ASPA)
1986. All animal experiments were approved by the Animal Welfare and Ethical Review Body (AWERB) at the University of Cam-
bridge. InsMycERTAM; Bcl-xL animals have been previously described (Pelengaris et al., 2002). Generation of WT Ngn3eYFP and
6S-A Ngn3eYFP mice is described in Figure S2. Knock-in WT Ngn3eYFP and 6S-A Ngn3eYFP animals were generated by embryonic
stem cell targeting of the endogenous Ngn3 locus. A PGK-driven puromycine resistance cassette has been used to select targeted
ES clones and removed after initial crossing with Flpase mice (Farley et al., 2000) The newly generated WT Ngn3eYFP and 6S-A
Ngn3eYFP alleles have been constitutively recombined into the endogenous Ngn3 locus by crossing with a PGK-Cre line (Lallemand
et al., 1998).
Xenopus laevis
Xenopus laevis were housed, bred and treated according to the Home Office guidelines, under the Animal Scientific Procedure Act
(ASPA) 1986. All animal experiments were approved by the Animal Welfare and Ethical Review Body (AWERB) at the University of
Cambridge. Xenopus laevis eggs and early stage embryos were obtained by standard methods (Vernon et al., 2003; Vosper
et al., 2009)
Cell Lines
Immortalized cell lines (HEK293, HEK293T, mPAC L20, MIN6) were grown in Dulbecco’s modified eagle medium (DMEM) supple-
mented with Glutamax, 10% foetal bovine serum (FBS) and penicillin/streptomycin (Pen/Strep)e2 Developmental Cell 41, 274–286.e1–e5, May 8, 2017
Primary Cell Cultures
Primary islet cultures were grown in low glucose (1g/L) DMEM supplemented with FBS and Pen/Strep. Primary ductal organoid
cultures were seeded in matrigel and grown in Advanced DMEM media supplemented with N2 and B27 (Lifesciences), 1.25 mM
N-Acetylcysteine (Sigma), 10 nM gastrin (Sigma) and the following growth factors: 50 ng/ml EGF (Peprotech), 5% RSPO1-condi-
tioned media, 25 ng/ml Noggin (R&D System), 100 ng/ml FGF10 (Peprotech) and 10 mM Nicotinamide (Sigma) (Huch et al., 2013).
METHOD DETAILS
Mouse Genotyping
Recombinant eYFP-containing alleles were amplified using the following primers: forward, Ngn3-Fw 5’-TACATCTGGGCACTGACT
CAGA-3’ and reverse Ngn3-eYFP-Rv 5’-GTCGTCCTTGAAGAAGATGGTG-3’; un-recombined wild-type allele was identified using
the same forward primer and the reverse primer Ngn3-Rv 5’-CTTGGAGCGAGAGTTTGATGTG-3’. PCR condition were 30 cycles
of 94oC/10sec; 60oC/20sec; 72oC/30sec. Distinction between WT and 6SA Ngn3 has been performed by sequencing the amplified
PCR product with the primer 5’-CATAGCGGACCACAGCTTCT-3’ or by cutting with restriction enzyme BglI.
Plasmid Constructs
Phosphomutant versions of Ngn3 were obtained by site-directed mutagenesis (QuickChange II Site-Directed Mutagenesis Kit, Stra-
tagene) of amurine pCS2-Ngn3 expression plasmid. 6S-ANgn3 carriesmutations in positions S14, S38, S160, S174, S183 and S199.
2S-A Ngn3 exhibits mutations in S183 and S187. HA-tagged wild type and mutants Ngn3 have been cloned by introducing the
following sequence at Ngn3 C-terminus: 5’-TACCCATACGATGTTCCAGATTACGCTTAA-3’. Lentiviral vectors have been obtained
by subcloning Ngn3 coding sequence into pLVX-TREG (Clontech).
Protein Phosphorylation Analysis
In vitro translated (IVT) radiolabelled proteins were incubated with interphase (I) or mitotic (M) Xenopus egg extracts. HA-tagged WT
and 6S-A Ngn3 proteins were collected 24 hours post transfection and analysed by SDS-PAGE, using rat anti-HA-Peroxidase
(1:1000; Roche) and mouse anti-tubulin (1:1000, Sigma). CyclinB D90 was produce in E. Coli, purified and incubated with IVT
Ngn3 at 21C for 40 minutes. Endogenous Ngn3 from E14 mouse pancreas was detected with rabbit anti-Ngn3 antibody (1:600;
kind gift from Dr Helena Edlund, Figures 1F and S1C) or mouse anti-Ngn3 (1:500, Developmental Studies Hybridoma Bank, Fig-
ure S2B). Phosphatase treatment was performed by 30-minute incubation at 30C with 400 units of Lambda Protein Phosphatase
(NEB). Pancreatic ductal mPAC cells expressing HA-tagged WT-Ngn3 were treated with Roscovitine (Selleckchem) and Palbociclib
(Selleckchem) at different concentrations for 24 hours.
Protein Stability Assay
Mouse insulinoma MIN6 cells overexpressing WT, 2S-A and 6S-A Ngn3 were treated with cycloheximide (10mg/ml). Proteins were
collected at different time points after treatment and lysed in RIPA-like lysis buffer (50mM Tris-HCl, pH 8; 150mM NaCl; 0.5%
NP40 Igepal; 10% Glycerol; protease and phosphatase inhibitor cocktails (Roche; Calbiochem)). Proteins were separated on
SDS-PAGE and immmunoblotted with rat anti-HA-Peroxidase (1:1000; Roche) andmouse anti-tubulin (1:1000, Sigma). Protein levels
were quantified with ImageJ software (n=3). Half-lives were calculated using first-order kinetics (Prism).
In Vitro Kinase Assay
In vitro kinase assay has been performed by incubating in vitro translated HA-taggedWT and 6S-A Ngn3 proteins with human recom-
binant CDK/CYCLINs (0.5mMfinal concentration of CDK4/CYCLIND1, CDK2/CYCLINA, CDK1/CYCLINB from ThermoFisher; CDK2/
CYCLINE1 fromAbcam) in the presence of 10 mMATP for 1 hour at 30C. In vitro translation was performed in the presence of 800mM
LiCl to reduce potential phosphorylation in reticulocyte lysate. Samples were resolved by SDS-PAGE and protein detected with anti-
HA antibody.
Pancreatic Organoid Cell Culture
Pancreatic ducts were isolated from the pancreas of adult mice. Pancreatic digestion, duct isolation and organoid culture were per-
formed as previously described (Huch et al., 2013). Briefly, chopped pancreas was incubated for 45-60 minutes at 37 C in collage-
nase/dispase dissociation Medium (1% in DMEM media (Gibco), supplemented with 1% FBS (Gibco) and Collagenase type XI
0.012% (w/v) (Sigma), dispase 0.012% (w/v) (Gibco)). Single ducts were manually picked, re-suspended with Matrigel (BD Biosci-
ence) and seeded. Culture media is composed of AdDMEM/F12 (Invitrogen) supplemented with N2 and B27 (Lifesciences),
1.25mM N-Acetylcysteine (Sigma), 10nM gastrin (Sigma) and the following growth factors: 50 ng/ml EGF (Peprotech), 5%
RSPO1-conditioned media, 25ng/ml Noggin (R&D System), 100 ng/ml FGF10 (Peprotech) and 10mM Nicotinamide (Sigma).
Infection of Pancreatic Organoids
Pancreatic organoids were infected with a two-vector lentivirus-based Tet-on system (Clontech). Coding sequences for HA-tagged
WT and 6S-A Ngn3, fused with GFP-2A cleavage peptide sequence at their N-terminus, were cloned into the pLVX-TRE3G vector
(Clontech). Viruseswere generated in HEK293T cells, titratedwith the LentiX titration kit (Clontech) and used atmultiplicity of infectionDevelopmental Cell 41, 274–286.e1–e5, May 8, 2017 e3
of 10 for the transgene, or 20 for the transctivator Tet3G. Organoids were dissociated to small clusters by TrypLE (Gibco) treatment
for 10 min at 370C. Dissociated organoids were incubated with the viruses and 8mg/ml polybrene (Sigma) in expansion media sup-
plemented with 10mM ROCKI (Sigma) and spun for 1h at 300xG at room temperature. After spinoculation, infected organoids were
incubated in a cell culture incubator at 370C for 5-6 hours before plating in matrigel with fresh media supplemented with ROCKi.
RNA Sequencing of Pancreatic Organoids
Pancreatic organoids infected with GFP-Ngn3 (WT/6S-A) were dissociated to single cells by TrypLE treatment for 10 min at 370C.
Pools of 50 GFP+ cells were FACS sorted and collected into a 96 well plate containing lysis buffer. Library preparation for RNA
sequencing used the protocol for single cell RNA sequencing described and optimized in (Picelli et al., 2014; Wilson et al., 2015).
The Illumina Nextera XT DNA preparation kit was used to prepare libraries. Pooled libraries were sequenced using the Illumina HiSeq
4000 system (single-end 50 bp reads).
Islet Isolation
Mouse pancreatic islet isolation was performed as previously described (Li et al., 2009) with some modifications. Mice were eutha-
nized in accordance with ASPA 1986 guidelines. The abdominal internal region was exposed and in situ pancreatic digestion was
performed: a clamp was positioned on the top of the duodenal papilla to block the passage from the common bile and pancreatic
duct into the intestine. Pancreatic digestion was carried out by injecting collagenase-containing media (Low glucose DMEM (Medi-
atech), 10mMHepes buffer (Invitrogen), collagenase 0.8 mg/ml (Roche)) into the ductal trees. Inflated pancreata were then collected
and incubated at 37oC for 15 minutes in the collagenase media. Islet purification was performed by sequential filtration through a
250mm filter and density gradient cell separation using a combination of Histopaque media (H-1077 and H-1119, Sigma). Single
acinar cells and cell clusters smaller than 40mm were removed and pancreatic islets were manually handpicked. After O/N 37oC in-
cubation in culture media, islets were lysed for RNA extraction.
Immunohistochemistry
Embryonic stage 16 pancreatic buds were fixed in 4% paraformaldehyde (PFA) for 10 minutes at 4C, embedded in OCT and
sectioned at 10mm thickness using a cryostat (Leica). Primary antibodies: Insulin (guinea pig, 1:200, Abcam), Glucagon (mouse,
1:200, Abcam), Somatostatin (rabbit, 1:200, Dako), Ppy (goat, 1:200, Abcam), GFP (chicken, 1:600, Abcam), Ngn3 (goat, 1:100 Santa
Cruz), Epcam (APC conjugated, 1:600, eBioscience). Adult pancreata were dissected from age-matched animals older than 6 weeks
and fixed in 4% formalin (Sigma) O/N 4C. Pancreata were paraffin embedded and sectioned at 5mm thickness, 100mm apart.
Image Acquisition
Bright field and eGFP pictures of live cultures were taken with EVOS (LifeTechnologies) and ZOE (Biorad). Immunofluorescence pic-
tures of embryonic buds and adult pancreata were imaged using an automated system (Axioscan, Zeiss).
Analysis of Insulinoma Mouse Model
Adult Ins-cMycERTAM; Bcl-xL and the control Bcl-xL mice were injected IP with 1mg of Tamoxifen (Sigma) in oil every day for 7 days.
Blood glucose was measured after a nick in the tail vein using AlphaTRAK (Abbott). Pancreata were analysed as described in Quan-
tification and Statistical analysis.
Xenopus laevis Gene Expression
Xenopus laevis eggs were obtained by standard hormone methods of induction, and subsequently fertilised in vitro. WT, 6S-A Ngn3
and c-Myc mRNAs were transcribed in vitro using the SP6 mMessage mMachine kit (Ambion). Two-cell-stage embryos were in-
jected into the animal pole withmRNA as indicated (0.75pgWT/6S-A Ngn3, 750pg c-Myc), with co-injection of 500 pgGFP to confirm
successful targeting. Embryos were subsequently cultured at 16C in Ficoll solution (4% w/v Ficoll, 0.2x MBS, 50mg/ml Gentamycin
in water) and staged according to the methods of Niewkoop and Faber. At stage 18, samples of four embryos were snap-frozen for
qRT-PCR analysis. Primer list is provided in Table S2.
Real Time PCR
Gene expression in organoid cultures, isolated islets and Xenopus laevis embryos were performed by real-time semi-quantitative
PCR. RNA was extracted with RNAesy mini kit (Qiagen) and retro-transcribed using QuantiTect Reverse Transcription kit (Qiagen;
for islets and Xenopus embryos) or High-Capacity cDNA Reverse Transcription Kit (Applied Biosystem; for organoids). Real time
PCRwas performed with QuantiFast SYBR Green PCR kit (Qiagen; for islets and Xenopus embryos) or with Taqman probes (Applied
Biosystem; for organoids). LightCycler (Roche) was used to run the PCR and analyse the data. EF1a or ActinB were used for endog-
enous reference gene control and the values were normalized to control levels. Relative quantification was determined according to
the DDc(t) method. Data are presented as means ± s.e.m. of normalized values from three independent experiments, unless other-
wise stated. The list of primers and Taqman probes is provided in Table S2.e4 Developmental Cell 41, 274–286.e1–e5, May 8, 2017
Chromatin Immunoprecipitation (ChIP)
ChIP experiments were performed onmPAC cell extracts, 24 hours after transfection with either HA-taggedWT or 6S-A Ngn3. Chro-
matin-protein complexes were cross-linked with 1% formaldehyde. Five micrograms of rabbit anti-HA antibody (Abcam) or control
anti-IgG (Abcam) were used per ChIP reaction and quantified using SYBR Green mix. The signal over background normalisation
method was used to quantify immunoprecipitated DNA. Primer list is provided in Table S2.
QUANTIFICATION AND STATISTICAL ANALYSIS
Figure Legends describe the statistical test and the associated parameters used to analyse the data. Asterisks indicate statistical
significance as explained in each figure legend (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001).
Analysis of Embryonic and Adult Pancreas
The percentage of hormone positive areas in the embryonic pancreatic buds was quantified using ZEN software (Zeiss). Values
are shown as means ± s.e.m of 4 pancreatic buds from 3 different litters. Insulin and glucagon positive areas in the adult
pancreas were calculated using ZEN software (Zeiss) and shown as a percentage over total DAPI area. Values are means ± s.e.m
n=4 from 6-8 sections for each animal, 100mm apart. Total number of islets and islet size distribution were calculated using ZEN soft-
ware (Zeiss). The optimized ZEN programme calculated islet size by creating amask over insulin plus glucagonmerged areas. Values
are means ± s.e.m n=4 from 6-8 sections for each animal, 100mm apart.
Analysis of the Insulinoma Pancreata
Hormone intensity in the Ins-cMycERTAM; Bcl-xL and Bcl-xL animals was calculated using ZEN software (Zeiss) and normalized for
the total islet area analyzed. At least 100 islets per condition were quantified, coming from 2-6 different sections (100mm apart) for
each animal from at least 3 different animals. Values are means ± s.e.m nR3 different animals for each genotype. Islet area was
calculated using ZEN software (Zeiss) from H&E stained tissue sections. nR3 different animals each genotype (2-11 sections
each animal).
RNA Sequencing Analysis
Reads were aligned using G-SNAP 30 and the mapped reads were assigned to Ensembl genes (release 81) by HTSeq. To identify
poor quality samples, three metrics were used: (1) the proportion of reads aligned to spike ins, (2) the number of endogenous reads,
and (3) the number of features with more than 0 read. We filtered for cells with (1) less than 30% reads aligned to spike ins, (2) more
than 1000000 endogenous reads, and (3) more than 10000 detected features. We only considered genes that were detected in at
least 5 samples (including technical and biological repeats), with a variance greater than 0. Based on this, two samples were not
considered for downstream analysis. Reads were normalised using size factor normalisations as implemented in the scran package
(Lun et al., 2016) (scran: Methods for Single-Cell RNA-Seq Data Analysis. R package version 1.2.0). Differential expression analysis
was performed using the DESeq2 package, where technical repeats were merged (Love et al., 2014).
DATA AND SOFTWARE AVAILABILITY
Deposited Data
The accession number for the sequencing data reported in this paper is GEO: GSE96707.Developmental Cell 41, 274–286.e1–e5, May 8, 2017 e5
